{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019629","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.729167+00:00","generated_at":"2026-06-15T11:27:28.191125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M","bullets":["Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.","Tyvaso DPI contributed $23M in revenue (collaborations/services $11.4M, royalties $11.7M).","Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M (acquired mid-2022).","Loss from operations improved 72% to $6M; cash and investments $166.6M at March 31.","CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial to start H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019629","json":"https://secwatch.observer/filing/0000950170-23-019629.json","markdown":"https://secwatch.observer/filing/0000950170-23-019629.md","text":"https://secwatch.observer/filing/0000950170-23-019629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/0000950170-23-019629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/mnkd-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:27:28.191125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f95e6e165835a41f72ce64425ed08f03301c3c5e","claim":"MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.","evidence_excerpt":"(EX-99.1) --- EX-99 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/0000950170-23-019629-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$41 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}